BeOne cashes in its Imdelltra royalty
Meanwhile, Royalty Pharma stakes $885m on $2.8bn sales by 2035.
Meanwhile, Royalty Pharma stakes $885m on $2.8bn sales by 2035.
At least 15 dual-payload ADCs will be discussed.
Novel targets including Ly6E and LRRC15 feature alongside more popular mechanisms.
Data suggest a path forward for olomorasib plus Keytruda and chemo in PD-L1 low and negative patients.
Western data on EO-3021 fail to live up to the billing of a Chinese trial.